News

CRN: Majority of Americans continue dietary supplement regimen despite economic slump

BY DSN STAFF

WASHINGTON According to a survey released last week, 65% of adult consumers take dietary supplements, up slightly from 64% in 2008, the Council for Responsible Nutrition announced. And when asked if the economy had affected their household’s dietary supplement purchasing habits, nearly 74% of those surveyed responded that it had not.

“We’re pleased that consumers place emphasis on their health, even in uncertain economic times, and that dietary supplements continue to play a role in their overall wellness regimen,” stated Judy Blatman, SVP communications, CRN. “According to our survey, consumers, including supplement users, report to be taking necessary steps towards good health, such as trying to eat a balanced diet and getting regular exercise. We’re encouraged that dietary supplements continue to be a part of that equation for many.”

According to results from the 2009 CRN Consumer Survey on Dietary Supplements, the economy did prompt 27% of dietary supplement consumers to alter their supplement purchasing habits.  Among that group, purchasing habits changed in the following ways:

  • 59% reported they are purchasing fewer supplements as a means to save money;
  • 31% indicated they are now purchasing less expensive brands;
  • 26% said they have been purchasing store brand supplements;
  • 23% indicated they rely on coupons and other value-added promotions;
  • 22% responded they only buy supplements when they are on sale;
  • 5% responded they are purchasing more supplements to maintain health; and
  • 4% responded they have stopped purchasing supplements because of the economy.

The 2009 CRN Consumer Survey on Dietary Supplements was conducted Aug. 26 through Sept. 1 by Ipsos Public Affairs and funded by CRN. The survey was conducted on-line and included a national sample of 2,043 adults aged 18 and older from Ipsos’ U.S. on-line panel.  The survey has been conducted annually since 2000.

KelloggsDRSNhttp://www.centerstoregrowth.com

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Hy-Vee celebrates the other white meat

BY Alaric DeArment

WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.

October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.

 

“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Patients prefer new diabetes drug Victoza over its competitor, survey finds

BY Alaric DeArment

MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.

According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.

Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.

“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?